

Supplementary Data

SUPPLEMENTARY TABLE S1. PRIOR AND CONCOMITANT
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
MEDICATIONS, SAFETY ANALYSIS SET

	<i>Placebo</i> (n = 131)	<i>SHP465</i> <i>MAS</i> (n = 132)
Prior ADHD medications used by $\geq 2\%$ of participants (either treatment arm), <i>n</i> (%)		
Methylphenidate	61 (46.6)	61 (46.2)
Lisdexamfetamine	40 (30.5)	42 (31.8)
Immediate-release MAS	40 (30.5)	33 (25.0)
Dexmethylphenidate hydrochloride	12 (9.2)	19 (14.4)
Guanfacine	14 (10.7)	14 (10.6)
Investigational drug	10 (7.6)	10 (7.6)
Atomoxetine hydrochloride	8 (6.1)	7 (5.3)
Clonidine	7 (5.3)	5 (3.8)
Concomitant ADHD medications used by $\geq 2\%$ of participants (either treatment arm), <i>n</i> (%)		
Lisdexamfetamine	7 (5.3)	9 (6.8)
Immediate-release MAS	9 (6.9)	8 (6.1)
Methylphenidate	1 (0.8)	6 (4.5)

ADHD, attention-deficit/hyperactivity disorder; MAS, mixed amphetamine salts.